A research team has evaluated the real-world impact of a community-based pneumococcal vaccination support program for older ...

There have been some reports of necrosis at the injection site following receipt of the 23-valent pneumococcal vaccine, but the vaccine’s overall benefit-risk balance “remains favorable,&rdquo ...

MORE. Politics. All Foreign Affairs Cross-strait ...

A research team has evaluated the real-world impact of a community-based pneumococcal vaccination support program for older adults conducted in Sera ...

RAHWAY, N.J., October 16, 2024--Merck’s CAPVAXIVE (Pneumo. 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease ...

RAHWAY, N.J., October 23, 2024--CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older ...

In the STRIDE-10 study, Merck’s V116—which is a 21-valent conjugate vaccine designed for adults—stacked up favorably against PPSV23, a 23-valent polysaccharide vaccine that was approved back ...

23-valent pneumococcal polysaccharide vaccine (PPSV23; Merck). The indications and schedules for the vaccines vary. All four vaccines are approved for adults.

| Apr. 11, 2025 06:38 ...

The trial evaluated the immunogenicity, safety and tolerability of CAPVAXIVE compared to PCV15 (pneumococcal 15-valent conjugate vaccine) in combination with PPSV23 (pneumococcal 23-valent ...